Differential proteomics analysis of oligodendrogliomas and astrocytomas using iTRAQ quantification
- Published
- Accepted
- Subject Areas
- Neuroscience, Neurology
- Keywords
- astrocytomas, oligodendrogliomas, Biomarker, Rho Family GTPases
- Copyright
- © 2016 Lin et al.
- Licence
- This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ Preprints) and either DOI or URL of the article must be cited.
- Cite this article
- 2016. Differential proteomics analysis of oligodendrogliomas and astrocytomas using iTRAQ quantification. PeerJ Preprints 4:e2179v1 https://doi.org/10.7287/peerj.preprints.2179v1
Abstract
Background: Astrocytomas and oligodendrogliomas are two types of primary Central nervous system (CNS) tumors. Because of the cytoarchitectural variability and lacking of accurate differential diagnosis biomarkers, distinguishing between these neoplasms remains a challenge. Method: In this study, we utilized the tumor tissue proteome to distinguish the astrocytomas and oligodendrogliomas. The protein samples from astrocytomas and oligodendrogliomas tumor tissues were analyzed by 2DLC/MS/MS and isobaric tags for relative and absolute quantitation (iTRAQ) quantification. The differential proteins were analyzed by IPA software, and three identified differential proteins were validated by Western Blot. Results: A total of 2189 proteins were identified, including 150 upregulated and 103 downregulated in astrogliomas compared to oligodendrogliomas. By bioinformatics analysis, compared to oligodendrogliomas, the astrocytomas is more likely tend to cell proliferation, migration and the tumor angiogenesis, indicating astrocytomas was more malignant than the oligodendrogliomas. Pathway analysis showed that members of Rho Family GTPases were remarkably changed between astrocytomas and oligodendrogliomas. Two member of Rho family of GTPases, Cell division control protein 42 homolog (CDC42) and Transforming protein RhoA (RHOA) were over-expressed in astrocytomas and oligodendrogliomas, respectively. Discussion: Above data indicated that the differential proteome could be useful to distinguish between astrocytomas and oligodendrogliomas, especially the Rho family of GTPases. Differential proteome could partially reflect the pathological characteristics of these two diseases.
Author Comment
This is a submission to PeerJ for review.
Supplemental Information
Distribution of proteins fold change in astrocytomas vs oligodendrogliomas
Supplementary Figure 1: Distribution of proteins fold change in astrocytomas vs oligodendrogliomas.
Qualitative protein list of oligodendrogliomas and astrocytomas proteome
Supplementary Table 1: Qualitative protein list of oligodendrogliomas and astrocytomas proteome.
Quantitative protein and peptide list of oligodendrogliomas and astrocytomas proteome
Supplementary Table 2: Quantitative protein and peptide list of oligodendrogliomas and astrocytomas proteome.
Differential proteins between oligodendrogliomas and astrocytomas
Supplementary Table 3: Differential proteins between oligodendrogliomas and astrocytomas .
Detail protein list classified by biological functions and pathway analysis by IPA in oligodendrogliomas and astrocytomas
Supplementary Table 4: Detail protein list classified by biological functions and pathway analysis by IPA in oligodendrogliomas and astrocytomas